Article thumbnail

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients

By Wajeh Y. Qunibi, Carlos Martinez, Mark Smith, Joseph Benjamin, Antoinette Mangione and Simon D. Roger

Abstract

Background. Iron deficiency is a common cause of anaemia and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent chronic kidney disease (ND-CKD) patients. Current intravenous iron agents cannot be administered in a single high dose because of adverse effects. Ferric carboxymaltose, a non-dextran parenteral iron preparation, can be rapidly administered in high doses

Topics: Original Article
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:3084440
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
  2. (1996). A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int
  3. (2006). A randomized controlled trial of oral versus intravenous iron in chronic kidney disease.
  4. (2001). A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. N e p h r o lD i a lT r a n s p l a n t
  5. (1994). Cefotetan-induced hemolytic anemia causing severe hypophosphatemia.
  6. (2003). Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (≥250 mg) administration.
  7. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidneydiseasenotondialysis.NephronClinPract2005;100:c55–c62
  8. (2003). Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
  9. (2003). Controversies in iron management.
  10. (2001). Ferrlecit® [package insert].
  11. (2009). FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
  12. (2005). For the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int
  13. (1998). Hereditary spherocytosis associated with severe hypophosphatemia in patients recovering from aplastic crisis. Rinsho Ketsueki
  14. (2005). Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant
  15. (2003). Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. Nephrology
  16. (1998). Interactions among iron, calcium, phosphorus and magnesium in the nutritionally irondeficient rat. Exp Physiol
  17. (2007). Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol
  18. (2005). Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study.
  19. (2001). Intravenous iron sucrose: establishing a safe dose.
  20. (1996). Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
  21. (2006). Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin. Int Urol Nephrol
  22. (2002). Iron status and hemoglobin level in chronic renal insufficiency.
  23. (2000). Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. JA mS o c Nephrol
  24. (2001). Oral repletion of iron induces free radical mediated alterations in the gastrointestinal tract of rat. Mol Cell Biochem
  25. (1981). Physiological and biochemical effects of iron deficiency on rat skeletal muscle.
  26. (2010). Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 6.
  27. (1996). Regular low-dose intravenous iron therapyimproves responsetoerythropoietinin haemodialysispatients. Nephrol Dial Transplant
  28. (2003). Safety in iron management.
  29. (2008). Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int
  30. (2000). Severe hypophosphatemia duringhematopoieticreconstitutionafterallogeneicperipheralbloodstem cell transplantation. Bone Marrow Transplant
  31. (1999). Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
  32. (2008). SpinowitzBS,KauszAT,BaptistaJetal.Ferumoxytolfor treatingiron deficiency anemia in CKD.
  33. (1999). Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl
  34. (1995). Sunder-PlassmannG,HörlWH.Importanceof ironsupplyforerythropoietin therapy. Nephrol Dial Transplant
  35. (2003). Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol
  36. (2009). The pharmacology and safety profile of ferric carboxymaltose (Ferinject(r)): structure/reactivity relationships of iron preparations.
  37. (2006). Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant